Stockreport
HSBC Downgrades Biogen Inc. (BIIB) to Reduce Despite Pipeline Progress [Yahoo! Finance]
Last biogen inc. earnings: 4/22 07:12 am
Check Earnings Report
US:NASDAQ Investor Relations: biogen.com/en_us/investors.html
On December 10, TheFly reported that HSBC downgraded BIIB from Hold to Reduce, and lowered its price target to $143, citing concerns that BIIB's reliance on royalty streams and challenges in its core business could weigh on future earnings and growth. HSBC's analysis highlighted margin pressure from declining royalty revenue and limited near-term earnings improvement potential, despite other progress at the company. Despite this downgrade, Biogen Inc. (NASDAQ:BIIB) has reported a series of recent operational and clinical developments: LEQEMBI (lecanemab), the company's Alzheimer's disease therapy developed with Eisai, was included in China's new Commercial Insurance Innovative Drug List on December 8, which is expected to expand market access and potential patient coverage starting January 1, 2026. Eisai and BIIB have presented data at scientific meetings such as CTAD 2025 on December 3, demonstrating continued benefits of LEQEMBI maintenance treatment in early Alzheimer's diseas
[Read more]
| IMPACT SNAPSHOT | EVENT TIME: | BIIB | ||||
|---|---|---|---|---|---|---|
|
Last Price
|
Price Change
|
Price Change %
|
Volume Shares
|
Max Up
|
Max Down
|
Volume Ratio
%
|
Performance comparison
Updated
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| LAST PRICE | ||
| VWAP | ||
|
High:
|
MAX UP |
High:
|
|
Low:
|
MAX DOWN |
Low:
|
|
%
|
POST NEWS RANGE |
%
|
|
|
PRICE CHANGE |
|
|
|
PRICE CHANGE PERCENTAGE |
|
|
|
S&P 500 (SPX) |
|
|
%
|
VOLUME RATIO |
%
|
| VOLUME (SHARES) | ||
| TICKS | ||
|
|
AVG SHARES PER TRADE |
|
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Be the first to know
Opt in for alerts from News Quantifed
Opt-in for
BIIB alerts
BIIB alerts
from News Quantified
Movers & Shakers
The biggest gainers and losers and WHY it moved
BIIB alerts
High impacting Biogen Inc. news events
Weekly update
A roundup of the hottest topics
BIIB
NEWS
NEWS
- Biogen (NASDAQ:BIIB) had its price target raised by analysts at BMO Capital Markets from $150.00 to $165.00. They now have a "market perform" rating on the stock.[MarketBeat]
- Biogen (NASDAQ:BIIB) was given a new $156.00 price target on by analysts at Morgan Stanley.[MarketBeat]
- Canadian HTA Assessments Recognize Therapeutic Value of QALSODY™ (tofersen injection) and its Potential to Modify Disease Progression in Individuals Living with SOD1-ALS [Yahoo! Finance][Yahoo! Finance]
- Biogen (NASDAQ:BIIB) was downgraded by analysts at Hsbc Global Res from a "hold" rating to a "moderate sell" rating.[MarketBeat]
- Biogen (NASDAQ:BIIB) had its price target raised by analysts at Wells Fargo & Company from $155.00 to $190.00. They now have an "equal weight" rating on the stock.[MarketBeat]
- More
BIIB
SEC Filings
SEC Filings
- 12/3/25 - Form 4
- 11/13/25 - Form SCHEDULE
- 11/10/25 - Form SCHEDULE
- BIIB's page on the SEC website
- More